News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Tony Pezzano

Advertisement

Articles by Tony Pezzano

Preparing for Competitive Challenges to Biologics with Expiring Market Exclusivity

ByMichael Dougherty,Tony Pezzano
January 31st 2020

Guidelines on how innovators can assert patents to protect their products’ exclusivity while avoiding claims from competitors and the FTC that their conduct runs afoul of U.S. antitrust law.

Advertisement

Latest Updated Articles

  • Preparing for Competitive Challenges to Biologics with Expiring Market Exclusivity
    Preparing for Competitive Challenges to Biologics with Expiring Market Exclusivity

    January 31st 2020



Advertisement
Advertisement

Trending on PharmExec

1

AI has Redefined Healthcare Communication — and There’s No Opting Out

2

How FDA's Removal of the Two-Trial Requirement Affects Development Programs

3

FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer

4

Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals

5

Novo Nordisk Signs Deal with Hims & Hers

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us